The National Hemophilia Foundation and the Hemophilia Federation of America continue to follow up on issues arising from Genentech’s recent announcement regarding reports of particulate matter in vials of Hemlibra.
Today, Genentech provided the following statement regarding reports of particulate matter in vials of Hemlibra.
NHF presented Awards of Excellence to medical professionals, chapter leaders, advocates, and volunteers at the Awards Ceremony at the 2019 Bleeding Disorders Conference in Anaheim, CA.
More than 2,500 attendees gathered in Anaheim, CA to gain valuable information and support.
A brief update to the community concerning a recent meeting with the FDA, and additional resources that the FDA provided.
Recently there has been a lot of news related to the safety of the bleeding disorders community. HFA & NHF are working together to address the issues important to patients.
NHF and HFA have received additional information from Bayer regarding the Kogenate FS recall.
Genentech Patient Foundation responded to questions from NHF and HFA.
NHF and HFA have sent a letter to Genentech and Medvantx asking for further information on how the error occured.
Ancillary supplies shipped by a specialty pharmacy, Medvantx, to a specific group of patients receiving Hemlibra through the Genentech Patient Foundation contained incorrect length injection needles.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car